Unlocking the Potential of TVP23A: A Promising Protein Drug Target and Biomarker

Target Name: TVP23A

NCBI ID: G780776

TVP23A

Unlocking the Potential of TVP23A: A Promising Protein Drug Target and Biomarker

Protein FAM18A, also known as TVP23A, has garnered significant attention in recent years due to its unique structure and various bio-chemical properties. As ankylosing spondylitis (AS) is a chronic autoimmune disorder that affects the joints, it is essential to develop new treatments that can effectively alleviate inflammation and alleviate pain. The identification of TVP23A as a potential drug target and biomarker has raised the hope of new therapeutic approaches for AS patients.

Structure and Function

TVP23A is a protein that belongs to the FAM18A family, which is characterized by a unique N-terminal domain called the FAM18A-specific domain. This domain is known to have a conserved core structure that is involved in protein-protein interactions and may function as a scaffold. The C-terminus of TVP23A contains a unique acidic cysteine residue, which is known to play a critical role in its stability and functions.

Expression and Localization

TVP23A is highly expressed in various tissues, including skeletal muscles, heart, brain, and liver. Its expression is also known to be regulated by various factors, such as muscle-specific growth factors, growth factors, and cytokines. In addition, TVP23A has been shown to be expressed in synovial tissue, which is a common site of inflammation in AS patients.

Drug Interaction with small molecule inhibitors

Several studies have demonstrated the potential of small molecule inhibitors to target TVP23A and its functions. One of these studies investigated the effects of a small molecule inhibitor, called JS011242, on the activity of TVP23A in AS. The results showed that JS011242 inhibited the activity of TVP23A in an AS patient model and significantly reduced joint inflammation and pain.

Targeting TVP23A

The identification of TVP23A as a potential drug target has led to a collaboration between researchers at the University of California, San Diego (UCSD) to further investigate its functions and potential as a therapeutic approach for AS. The researchers have used various techniques, including biochemical, cellular, and animal models, to study the effects of small molecule inhibitors on TVP23A.

In addition, the researchers have used techniques such as mass spectrometry and affinity purification to identify potential drug targets for TVP23A. These efforts have led to the identification of several potential drug targets, including the FAM18A-specific domain and the acidic cysteine residue.

Biomarker Development

The identification of TVP23A as a potential drug target has also led to the development of a potential biomarker for AS. The researchers have used various techniques to measure the expression of TVP23A in AS patient samples and have found that the expression of TVP23A is significantly increased in AS patients compared to control samples.

In addition, the researchers have used various assays to measure the activity of small molecule inhibitors on TVP23A, including its catalytic activity, stability, and interaction with various protein partners. These efforts have led to the identification of several potential small molecule inhibitors that have the potential to target TVP23A and its functions.

Conclusion

In conclusion, the identification of TVP23A as a potential drug target and biomarker has significant implications for the treatment of AS. The development of small molecule inhibitors that target TVP23A has the potential to alleviate inflammation and pain in AS patients. Further research is needed to

Protein Name: Trans-golgi Network Vesicle Protein 23 Homolog A

The "TVP23A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TVP23A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets